Table 4.
Analysis of factors affecting PFS
| Items | Cox’s proportional hazard regression model | |||
|---|---|---|---|---|
|
| ||||
| P value | HR | 95% CI | ||
|
| ||||
| Lower | Higher | |||
| Univariate Cox’s regression | ||||
| Therapy | ||||
| Apatinib | Reference | - | - | - |
| Apatinib plus cTACE | 0.004 | 0.196 | 0.066 | 0.587 |
| Apatinib plus DEB-TACE | <0.001 | 0.068 | 0.019 | 0.240 |
| Age (>60 years vs. ≤60 years) | 0.763 | 1.124 | 0.526 | 2.400 |
| Gender (male vs. female) | 0.249 | 1.592 | 0.722 | 3.509 |
| Wight (>60 kg vs. ≤60 kg) | 0.804 | 1.099 | 0.523 | 2.309 |
| HBV (positive vs. negative) | 0.862 | 1.068 | 0.508 | 2.247 |
| ECOG score (2 vs. 1) | 0.045 | 2.310 | 1.018 | 5.244 |
| Child-Pugh stage (B vs. A) | 0.677 | 1.207 | 0.498 | 2.924 |
| Number of intrahepatic tumors (>3 vs. ≤3) | 0.015 | 2.959 | 1.232 | 7.106 |
| Macroscopic vascular invasion (yes vs. no) | 0.462 | 1.347 | 0.609 | 2.980 |
| Tumor size (>5 cm vs. ≤5 cm) | 0.676 | 1.202 | 0.507 | 2.848 |
| Lymph node metastasis (yes vs. no) | 0.470 | 1.402 | 0.560 | 3.511 |
| Distant metastasis (yes vs. no) | 0.029 | 2.845 | 1.112 | 7.277 |
| TNM stage (IV vs. III) | 0.040 | 2.526 | 1.043 | 6.118 |
| CA199￡ (abnormal vs. normal) | 0.119 | 1.942 | 0.843 | 4.478 |
| Bile duct dilatation (yes vs. no) | 0.709 | 1.162 | 0.528 | 2.557 |
| Biliary drainage (yes vs. no) | 0.694 | 0.820 | 0.306 | 2.200 |
| Previous therapy (yes vs. no) | 0.993 | 0.996 | 0.431 | 2.302 |
| Forward stepwise multivariate Cox’s regression | ||||
| Therapy | ||||
| Apatinib | Reference | - | - | - |
| Apatinib plus cTACE | <0.001 | 0.090 | 0.025 | 0.325 |
| Apatinib plus DEB-TACE | <0.001 | 0.025 | 0.005 | 0.116 |
| ECOG score (2 vs. 1) | 0.001 | 6.213 | 2.221 | 17.382 |
| Distant metastasis (yes vs. no) | 0.002 | 5.417 | 1.863 | 15.750 |
| CA199￡ (abnormal vs. normal) | 0.017 | 3.012 | 1.218 | 7.449 |
Factors affecting PFS were analyzed by univariate and forward stepwise multivariate Cox’s proportional hazard regression model.
￡
normal: CA199 level ≤27.0 U/mL, abnormal: CA199 level >27.0 U/mL.
PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; cTACE, conventional transarterial chemoembolization; DEB-TACE, drug-eluting bead transarterial chemoembolization; HBV, hepatitis B virus; ECOG, Eastern Co-operative Oncology Group; CA199, carbohydrate antigen 199.